Nrx Pharmaceuticals Stock Revenue
| NRXP Stock | USD 1.35 0.04 3.05% |
NRX Pharmaceuticals fundamentals help investors to digest information that contributes to NRX Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of NRX Stock. The fundamental analysis module provides a way to measure NRX Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NRX Pharmaceuticals stock.
| Last Reported | Projected for Next Year |
NRX | Revenue |
NRX Pharmaceuticals Company Revenue Analysis
NRX Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of NRX
Projected quarterly revenue analysis of NRX Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of NRX Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in NRX Pharmaceuticals' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, NRX Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
NRX Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NRX Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NRX Pharmaceuticals could also be used in its relative valuation, which is a method of valuing NRX Pharmaceuticals by comparing valuation metrics of similar companies.NRX Pharmaceuticals is currently under evaluation in revenue category among its peers.
NRX Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in NRX Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of NRX Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing NRX Pharmaceuticals' value.| Shares | Wells Fargo & Co | 2024-09-30 | 2.7 K | Tower Research Capital Llc | 2024-09-30 | 2.5 K | Goss Wealth Management Llc | 2024-09-30 | 83.0 | Jpmorgan Chase & Co | 2024-09-30 | 50.0 | Harbour Investments, Inc. | 2024-09-30 | 47.0 | Ubs Group Ag | 2024-09-30 | 38.0 | Larson Financial Group, Llc | 2024-09-30 | 22.0 | Royal Bank Of Canada | 2024-09-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 240.3 K | Anson Funds Management Lp | 2024-09-30 | 142.5 K |
NRX Fundamentals
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.16 | ||||
| Current Valuation | 20.87 M | ||||
| Shares Outstanding | 12.09 M | ||||
| Shares Owned By Insiders | 23.56 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 667 K | ||||
| Price To Book | 2.90 X | ||||
| EBITDA | (30.02 M) | ||||
| Net Income | (30.15 M) | ||||
| Cash And Equivalents | 24.55 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 9.16 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | (1.42) X | ||||
| Cash Flow From Operations | (21.66 M) | ||||
| Short Ratio | 4.80 X | ||||
| Earnings Per Share | (2.11) X | ||||
| Target Price | 31.33 | ||||
| Beta | 1.27 | ||||
| Market Capitalization | 15.84 M | ||||
| Total Asset | 7.32 M | ||||
| Retained Earnings | (253.15 M) | ||||
| Working Capital | (12.16 M) | ||||
| Net Asset | 7.32 M |
About NRX Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NRX Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NRX Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NRX Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with NRX Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NRX Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with NRX Stock
Moving against NRX Stock
| 0.84 | DRUG | Bright Minds Biosciences Trending | PairCorr |
| 0.64 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.59 | VCYT | Veracyte | PairCorr |
| 0.56 | VERA | Vera Therapeutics | PairCorr |
| 0.46 | DSGN | Design Therapeutics | PairCorr |
The ability to find closely correlated positions to NRX Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NRX Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NRX Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NRX Pharmaceuticals to buy it.
The correlation of NRX Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NRX Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NRX Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NRX Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.